Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nefazodone
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nefazodone is an antidepressant classified as a phenylpiperazine and serotonin modulator. It is primarily used to treat depression, including major depressive disorder. Its mechanism of action involves inhibiting the neuronal uptake of serotonin and norepinephrine, thereby increasing their levels in the brain. Additionally, nefazodone acts as an antagonist at central 5-hydroxytryptamine type 2 (5-HT2) receptors and alpha1-adrenergic receptors, which may contribute to its therapeutic effects and side effect profile. Unlike selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), or monoamine oxidase inhibitors (MAOIs), nefazodone has a distinct chemical structure and pharmacological profile[1][3][4][5]. The drug was originally developed by Bristol-Myers Squibb.
- Brand names
- SerzoneNefadar
- Other names
- NefazodonaNefazodonum
02
Targets
ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on nefazodone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nefazodone.